Healthy
Conditions
Keywords
Probiotic, Digestive Health, Healthy, Nutrient analysis, Constipation
Brief summary
This trial will be investigating the effect for Floradapt Mature Immune Defense on nutrient uptake and digestive health in a healthy elderly population. Approximately 120 healthy older adults will be enrolled into the study and will consume either the probiotic or placebo supplement for 84 days and complete questionnaires as well as provide blood samples for nutrient uptake analysis (for 50 participants), immunological markers, and general markers of health. Saliva samples will be provided for analysis of sIgA and cortisol.
Interventions
DIETARY_SUPPLEMENTFloradapt Mature Immune Defense + Multivitamin
The product consists of two L. plantarum strains, KABP XXXX and KABP XXXX with a combined strength of \>1 x 10\^9 CFU. Participants will also consume a multivitamin.
DIETARY_SUPPLEMENTPlacebo + Multivitamin
No active ingredients + a multivitamin supplement
Sponsors
KGK Science Inc.
Kaneka Americas Holding Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
Randomized, double-blind, placebo-controlled, parallel study
Eligibility
Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
1. Males or females age 50 to 85 years, inclusive 2. BMI 18.5-29.9 kg/m2, inclusive 3. Participants must meet the following criteria regarding their bowel habits. This will be assessed at screening and confirmed at baseline: I. ≤ 5 complete BMs per week AND at least 25% of BMs are BSS type 1 or 2 collectively with excessive straining for most of the BMs (≥50%), defined as 3 minutes or more during BM, as assessed by the QI OR, II. At least 50% of bowel movements are Bristol Stool Scale (BSS) type 1 and 2 at screening and confirmed at baseline as assessed by the QI OR, III. ≤ 3 complete spontaneous BMs per week as assessed by the QI 4. Female participant is not of child bearing potential, which is defined as females who have had a hysterectomy or bilateral oophorectomy, complete endometrial ablation, bilateral tubal ligation or are post-menopausal (natural or surgically with \> 1 year since last menstruation) OR, Females of child-bearing potential must have a negative urine pregnancy test at screening and baseline and must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. A minimum of 3-months stable dose is required for females on a hormonal birth control. Acceptable methods of birth control include: I. Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) II. Double-barrier method III. Intrauterine devices IV. Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s) V. Vasectomy of partner (shown successful as per appropriate follow-up) 5. Albumin levels at screening between 25-50 g/L, inclusive. If albumin level \<35 g/L all other liver function tests must be within the normal range. 6. Healthy as determined by laboratory results, medical history, and physical exam by QI 7. Agrees to comply with all study procedures 8. Agrees to maintain current level of physical activity and diet throughout the study
Exclusion criteria
1. Women who are pregnant, breast feeding, or planning to become pregnant during the trial 2. Allergy or sensitivity to investigational product's active or inactive ingredients or milk 3. Chronic constipation 4. On prescribed laxatives 5. Current or history of clinically significant diseases of the gastrointestinal tract (examples include but are not limited to atrophic gastritis, celiac disease, gluten intolerance/sensitivity, inflammatory bowel disease) 6. Current or history of pancreatitis or short bowel syndrome 7. Current or history of malabsorption assessed by the QI 8. Major surgery in the past 3 months or individuals who have planned surgery during the course of the trial. Minor surgery will be considered on a case by case basis by QI 9. Cancer, except skin cancers completely excised with no chemotherapy or radiation with a follow up that is negative. Cancer in full remission for more than five years after diagnosis are acceptable. 10. Verbal confirmation of autoimmune disease or if immune-compromised 11. Verbal confirmation of HIV, hepatitis B/C positive diagnosis 12. Current or history of hypertension but on a stable dose medication for ≥ 2 months will be reviewed on a case-by-case basis by the QI. 13. Type I or type II diabetes or use of diabetes medication 14. Significant cardiovascular event in the past 6 months. No significant cardiovascular event on stable medication may be included after assessment by the QI on a case by case basis 15. History or currently with kidney and liver diseases assessed by QI on a case by case basis, with the exception of kidney stone history in participants who are symptom free for 1 year 16. Verbal confirmation of current or pre-existing thyroid condition. Treatment on a stable dose medication for over 3 months will be reviewed on a case-by-case basis by the QI 17. Difficulties swallowing medications 18. Verbal confirmation of bleeding disorder 19. Blood disorders as determined by laboratory results 20. Acute or chronic illness of concern to the QI 21. Clinically significant abnormal laboratory results at screening as assessed by QI 22. Current use of blood thinners, with the exception of ASA 81 mg or less 23. Current use of prescribed medications that may cause constipation or affect the study outcomes as assessed by QI 24. Use of over-the-counter (OTC) medications or supplements or consumption of foods/drinks that may affect the study outcomes, unless willing to undergo an appropriate washout period prior to baseline is agreed upon after assessment by the QI. 25. Medicinal use of marijuana 26. Recreational use of marijuana, unless willing to undergo a 30-day washout prior to baseline 27. Alcohol or drug abuse (\< 1 year) 28. High alcohol intake (average of \>2 standar3d drinks per day or \>10 standard drinks per week) 29. Use of narcotics 30. Illicit drug use in the past 6 months as assessed by the QI 31. Current uses of tobacco or related products unless cessation 60 days prior to baseline 32. Blood donation during or within 30 days following conclusion of clinical trial 33. Participation in a clinical research trial within 30 days prior to enrollment will be assessed case-by-case by the QI 34. Verbal confirmation of dementia or known neuropsychological condition that, in the QI's opinion, could interfere with study participation. 35. Individuals who are cognitively impaired and/or who are unable to give informed consent 36. Any other chronic or active or unstable medical condition, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The changes from baseline to day 84 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing serum levels of Iron | 84 days | — |
| The changes from baseline to day 42 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing serum levels of Iron | 42 days | — |
| The changes from baseline to day 84 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing serum levels of Calcium | 84 days | — |
| The changes from baseline to day 42 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing serum levels of Vitamin A | 42 days | — |
| The changes from baseline to day 42 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing serum levels of Calcium | 42 days | — |
| The changes from baseline to day 84 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing serum levels of Vitamin E | 84 days | — |
| The changes from baseline to day 42 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing serum levels of total protein | 42 days | — |
| The changes from baseline to day 42 between Floradapt Mature Immune Defense and placebo in digestive health as assessed by Gastrointestinal Symptoms Rating Scale (GSRS) | 42 days | Five symptom clusters depicted as Reflux, Abdominal pain, Indigestion, Diarrhoea and Constipation will be assessed from the combination of the 15 items in the questionnaire (Abdominal pains, Heartburn, Acid regurgitation, Sucking sensations in the epigastrium, Nausea and vomiting, Borborygmus, Abdominal distension, Eructation, Increased flatus, Decreased passage of stools, Increased passage of stools, Loose stools, Hard Stools, Urgent need for defecation, Feeling of incomplete evacuation). All the domains will be scored on a 4-point scale where 0 represented no symptoms and 3 represented severe symptoms. A lower score represents less symptoms. |
| The changes from baseline to day 84 between Floradapt Mature Immune Defense and placebo in digestive health as assessed by Gastrointestinal Symptoms Rating Scale (GSRS) | 84 days | Five symptom clusters depicted as Reflux, Abdominal pain, Indigestion, Diarrhoea and Constipation will be assessed from the combination of the 15 items in the questionnaire (Abdominal pains, Heartburn, Acid regurgitation, Sucking sensations in the epigastrium, Nausea and vomiting, Borborygmus, Abdominal distension, Eructation, Increased flatus, Decreased passage of stools, Increased passage of stools, Loose stools, Hard Stools, Urgent need for defecation, Feeling of incomplete evacuation). All the domains will be scored on a 4-point scale where 0 represented no symptoms and 3 represented severe symptoms. A lower score represents less symptoms. |
| The changes from baseline to day 42 between Floradapt Mature Immune Defense and placebo in bowel movements and stool consistency as assessed by daily bowel habits diary | 42 days | The Bowel Habit Diary consisted of a 7 items questionnaire for evaluating each bowel movement. Bristol Stool Scale is a seven-stool description and image scale within the Daily Bowel Habit Diary to assess stool shape and consistency (type 1 is separate hard lumps, where type 7 is watery stools with no solid pieces). Stool consistency is a bowel function indicator due to its correlation with colonic transit time. |
| The changes from baseline to day 84 between Floradapt Mature Immune Defense and placebo in bowel movements and stool consistency as assessed by daily bowel habits diary | 84 days | The Bowel Habit Diary consisted of a 7 items questionnaire for evaluating each bowel movement. Bristol Stool Scale is a seven-stool description and image scale within the Daily Bowel Habit Diary to assess stool shape and consistency (type 1 is separate hard lumps, where type 7 is watery stools with no solid pieces). Stool consistency is a bowel function indicator due to its correlation with colonic transit time. |
| The changes from baseline to day 42 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing serum levels of albumin | 42 days | — |
| The changes from baseline to day 84 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing serum levels of albumin | 84 days | — |
| The changes from baseline to day 84 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing serum levels of total protein | 84 days | — |
| The changes from baseline to day 42 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing serum levels of Vitamin E | 42 days | — |
| The changes from baseline to day 84 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing serum levels of Vitamin D | 84 days | — |
| The changes from baseline to day 42 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing serum levels of Vitamin D | 42 days | — |
| The changes from baseline to day 84 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing serum levels of Vitamin C | 84 days | — |
| The changes from baseline to day 42 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing serum levels of Vitamin C | 42 days | — |
| The changes from baseline to day 84 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing serum levels of Folate | 84 days | — |
| The changes from baseline to day 42 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing serum levels of Folate | 42 days | — |
| The changes from baseline to day 84 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing serum levels of Vitamin B12 | 84 days | — |
| The changes from baseline to day 42 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing serum levels of Vitamin B12 | 42 days | — |
| The changes from baseline to day 84 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing serum levels of Vitamin A | 84 days | — |
| The changes from baseline to day 84 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing plasma levels of CoQ10 | 84 days | — |
| The changes from baseline to day 42 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing plasma levels of CoQ10 | 42 days | — |
| The changes from baseline to day 84 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing plasma levels of Zinc | 84 days | — |
| The changes from baseline to day 42 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing plasma levels of Zinc | 42 days | — |
| The changes from baseline to day 84 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing plasma levels of Vitamin B6 | 84 days | — |
| The changes from baseline to day 42 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing plasma levels of Vitamin B6 | 42 days | — |
| The changes from baseline to day 84 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing serum levels of Magnesium | 84 days | — |
| The changes from baseline to day 42 between Floradapt Mature Immune Defense and placebo in nutrient uptake as determined by analyzing serum levels of Magnesium | 42 days | — |
Secondary
| Measure | Time frame |
|---|---|
| The changes in saliva immunological marker sIgA from baseline to day 84 between Floradapt Mature Immune Defense and placebo supplementation | 84 days |
| The change from baseline to day 84 between Floradapt Mature Immune Defense and placebo in quality of life (QoL) assessed by the SF-12v2 questionnaire | 84 days |
| The change from baseline to day 84 between Floradapt Mature Immune Defense and placebo in quality of life (QoL) assessed by Perceived Stress test | 84 days |
| The changes in plasma immunological marker CD4+from baseline to day 42 between Floradapt Mature Immune Defense and placebo supplementation | 42 days |
| The changes in plasma immunological marker CD4+from baseline to day 84 between Floradapt Mature Immune Defense and placebo supplementation | 84 days |
| The changes in plasma immunological marker CD8+from baseline to day 42 between Floradapt Mature Immune Defense and placebo supplementation | 42 days |
| The changes in plasma immunological marker CD8+from baseline to day 84 between Floradapt Mature Immune Defense and placebo supplementation | 84 days |
| The changes in plasma immunological marker CD19+ from baseline to day 42 between Floradapt Mature Immune Defense and placebo supplementation | 42 days |
| The changes in plasma immunological marker CD19+ from baseline to day 84 between Floradapt Mature Immune Defense and placebo supplementation | 84 days |
| The changes in plasma immunological marker CD56+ from baseline to day 42 between Floradapt Mature Immune Defense and placebo supplementation | 42 days |
| The changes in plasma immunological marker CD56+ from baseline to day 84 between Floradapt Mature Immune Defense and placebo supplementation | 84 days |
| The changes in saliva immunological marker sIgA from baseline to day 42 between Floradapt Mature Immune Defense and placebo supplementation | 42 days |
| The changes in saliva immunological marker cortisol from baseline to day 42 between Floradapt Mature Immune Defense and placebo supplementation | 42 days |
| The changes in saliva immunological marker cortisol from baseline to day 84 between Floradapt Mature Immune Defense and placebo supplementation | 84 days |
Other
| Measure | Time frame |
|---|---|
| Incidence of pre-emergent and post-emergent adverse events following 84-day between Floradapt Mature Immune Defense and placebo supplementation | 84 days |
| The change in red cell distribution width (RDW) after 84-day supplementation with Floradapt Mature Immune Defense or placebo | 84 days |
| The change in mean platelet volume (MPV) after 84-day supplementation with Floradapt Mature Immune Defense or placebo | 84 days |
| The change in mean corpuscular hemoglobin concentration (MCHC) after 84-day supplementation with Floradapt Mature Immune Defense or placebo | 84 days |
| The change in mean corpuscular hemoglobin (MCH) after 84-day supplementation with Floradapt Mature Immune Defense or placebo | 84 days |
| The change in mean corpuscular volume (MCV) after 84-day supplementation with Floradapt Mature Immune Defense or placebo | 84 days |
| The change in platelet count after 84-day supplementation with Floradapt Mature Immune Defense or placebo | 84 days |
| The change in hematocrit levels after 84-day supplementation with Floradapt Mature Immune Defense or placebo | 84 days |
| The change in hemoglobin levels after 84-day supplementation with Floradapt Mature Immune Defense or placebo | 84 days |
| The change in red blood cell (RBC) count after 84-day supplementation with Floradapt Mature Immune Defense or placebo | 84 days |
| The change in basophils after 84-day supplementation with Floradapt Mature Immune Defense or placebo | 84 days |
| The change in eosinophils after 84-day supplementation with Floradapt Mature Immune Defense or placebo | 84 days |
| The change in monocytes after 84-day supplementation with Floradapt Mature Immune Defense or placebo | 84 days |
| The change in lymphocytes after 84-day supplementation with Floradapt Mature Immune Defense or placebo | 84 days |
| The change in neutrophils after 84-day supplementation with Floradapt Mature Immune Defense or placebo | 84 days |
| The change in estimated glomerular filtration rate (eGFR) following 84-day supplementation with Floradapt Mature Immune Defense or placebo | 84 days |
| The change in electrolytes following 84-day supplementation with Floradapt Mature Immune Defense or placebo | 84 days |
| The change in creatinine following 84-day supplementation with Floradapt Mature Immune Defense or placebo | 84 days |
| The change in total bilirubin following 84-day supplementation with Floradapt Mature Immune Defense or placebo | 84 days |
| The change in aspartate aminotransferase (AST) following 84-day supplementation with Floradapt Mature Immune Defense or placebo | 84 days |
| The change in alanine aminotransferase (ALT) following 84-day supplementation with Floradapt Mature Immune Defense or placebo | 84 days |
| The change in heart rate when supplemented for 84-days with either Floradapt Mature Immune Defense or placebo | 84 days |
| The change in diastolic blood pressure when supplemented for 84-days with either Floradapt Mature Immune Defense or placebo | 84 days |
| The change in systolic blood pressure when supplemented for 84-days with either Floradapt Mature Immune Defense or placebo | 84 days |
Countries
Canada
Outcome results
None listed